Chemomab Therapeutics
CMMB
10 hedge funds and large institutions have $82.4M invested in Chemomab Therapeutics in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
23,704% more capital invested
Capital invested by funds: $346K → $82.4M (+$82M)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding
Funds holding: 5 → 10 (+5)
0.33% more ownership
Funds ownership: 0.01% → 0.34% (+0.33%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$128M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$6.3M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$4.66M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$3.07M |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$120K |
| 2 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$43K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$21K |
| 4 |
Morgan Stanley
New York
|
-$8.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $74M | +$128M | +644,544 | New |
|
|
MS
2
Maven Securities
St Helier,
Jersey
| $3.63M | +$6.3M | +31,641 | New |
|
|
CH
3
CVI Holdings
Wilmington,
Delaware
| $2.69M | +$4.66M | +23,438 | New |
|
|
BFM
4
Boothbay Fund Management
New York
| $1.77M | +$3.07M | +15,440 | New |
|
5
Renaissance Technologies
New York
| $202K | +$83.6K | +420 | +31% |
|
6
UBS Group
Zurich,
Switzerland
| $24K | +$41.6K | +209 | New |
|
|
7
Morgan Stanley
New York
| $10K | -$8.56K | -43 | -34% |
|
|
IF
8
Ironwood Financial
Tucson,
Arizona
| $5K | +$8.36K | +42 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | +$3.78K | +19 | New |
|
|
MIH
10
Meitav Investment House
Bene-Beraq,
Israel
| $239 | +$413K | +2,078 | New |
|
|
VF
11
Virtu Financial
New York
| – | -$120K | -1,088 | Closed |
|
|
RC
12
RegentAtlantic Capital
Morristown,
New Jersey
| – | -$43K | -391 | Closed |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$21K | -190 | Closed |
|
CMMB Hedge Fund Activity: Q1 2021 in Review
10 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2021, worth a combined $82.4M — up 23,704% from $346K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CMMB positions and 3 closed out — a net gain of 5 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $128M. The largest seller was Virtu Financial, exiting entirely with an estimated $120K sold.
- 10 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2021, up from 5 in Q4 2020.
- Funds reported $82.4M of Chemomab Therapeutics stock for Q1 2021, up 23,704% quarter-over-quarter.
- 8 funds opened new Chemomab Therapeutics positions in Q1 2021 and 3 closed out, a net change of +5 holders.
- The largest Chemomab Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $128M added.
- The largest Chemomab Therapeutics seller in Q1 2021 was Virtu Financial, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2021.